Post‐market drug safety evidence sources: an analysis of FDA drug safety communications
- 3 October 2012
- journal article
- letter
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 21 (10) , 1134-1136
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Potential Safety Signals and Their SignificanceArchives of internal medicine (1960), 2012
- ADHD Drugs and Serious Cardiovascular Events in Children and Young AdultsNew England Journal of Medicine, 2011
- Role of Postmarketing Surveillance in Contemporary MedicineAnnual Review of Medicine, 2011
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug AdministrationNew England Journal of Medicine, 2010
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or PioglitazoneJAMA, 2010
- The Effect of Aprotinin on Outcome after Coronary-Artery Bypass GraftingNew England Journal of Medicine, 2008
- Aprotinin during Coronary-Artery Bypass Grafting and Risk of DeathNew England Journal of Medicine, 2008
- The Risk Associated with Aprotinin in Cardiac SurgeryNew England Journal of Medicine, 2006
- Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival StudyJournal of Clinical Oncology, 2005
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003